What is semaglutide?
A medication that mimics GLP-1, your body’s natural fullness signal. You feel satisfied sooner and stay satisfied longer. This will support you to make changes to diet and exercise to help you lose weight.
If you have been putting off weight loss medication because you dislike needles, you are not alone. The Wegovy pill now offers an alternative, compared to how Wegovy injections are taken.
Why was an oral GLP-1 so difficult to develop?
Semaglutide is a peptide (a small protein), and stomach acid breaks down its structure. Pepsin, the main digestive enzyme, cuts it into fragments. What reaches the bloodstream bears no resemblance to what you swallowed.
Until 2019, every GLP-1 medication required injection. No one had found a way through the gut.
But semaglutide turned out to be an unusually good candidate for oral delivery. As a small protein molecule, it slips easily through the stomach lining. It stays in the body for about a week, which means daily dosing can smooth out the inevitable ups and downs in absorption. And it works at tiny concentrations, so even if only a fraction gets through, that fraction can still do its job.
How the Wegovy pill gets into your bloodstream: SNAC technology
The solution is a compound called SNAC, combined with semaglutide in each tablet.
As the tablet dissolves, SNAC forms a protective pocket where the tablet sits. It keeps your stomach’s digestive enzymes at bay just long enough for semaglutide to slip through. It also briefly opens a pathway through the stomach lining, letting the drug pass into your bloodstream.
Most oral drugs pass through the stomach and are absorbed in the small intestine. Semaglutide cannot survive that long. It has to get through before it leaves the stomach.
SNAC’s effect is temporary and fully reversible. Within about 30 minutes, your stomach returns to normal. Studies show no lasting changes to the stomach lining. The pathway opens, the drug gets through, and everything closes up again.
Why fasting is non-negotiable
Most oral medications are forgiving. Semaglutide is not.
SNAC is only effective when your stomach is empty. Food, coffee, tea, supplements, and excess water can break the protective pocket before semaglutide gets through. If that happens, the drug does not absorb.
The margin for error is narrower than with most medications you have taken. Studies show absorption drops dramatically when people eat too soon, drink too much water, or skip the overnight fast.
In some patients, no semaglutide was detected in their bloodstream. Not low levels, but zero. Digestion destroyed the drug before it had a chance to work.
In trials, someone is watching and reminding you. At home, a rushed morning or a forgotten rule is all it takes.
So the instructions on how to take Wegovy pills correctly are strict: take the tablet first thing in the morning after an overnight fast. Swallow with no more than 120ml of plain water and wait at least 30 minutes before eating or drinking anything else.
Why are the doses so much higher than the injection?
The Wegovy pill dosage schedule is 25mg daily at maintenance. The weekly injectable delivers 2.4mg. The difference is absorption, or rather, how little of it happens.
Only about 0.8% (less than 1%) of the swallowed dose reaches your bloodstream when taken correctly. An injection delivers roughly 89%. The maths is simple: you need a much higher dose by mouth.
Oral dosing also introduces variability. Your stomach’s acidity, how quickly food moves through, and whether you followed the fasting rules exactly all affect how much semaglutide reaches your bloodstream. Studies show this can vary by up to 85% from person to person and day to day.
Daily dosing compensates for this. Semaglutide accumulates in your system over time, reaching a steady level after about four to five weeks. Once there, missing the mark on one day does not derail the whole week. But only if you take it consistently.
Join now
Is the science proven?
In OASIS 4, researchers followed 307 adults with obesity or overweight for 64 weeks. Patients followed a reduced-calorie diet and exercise programme alongside taking oral Wegovy.
Participants achieved an average weight loss of 13.6%, compared to 2.2% with placebo (dummy pills). Where people fully adhered to treatment, the average loss was 16.6%.
Based on these results, the US Food and Drug Administration (FDA) approved oral Wegovy in December 2025. Oral semaglutide is now the first GLP-1 cleared for weight management as a tablet. The UK regulator (MHRA) is expected to complete its review in late 2026.
Regulators first approved SNAC in 2019 for Rybelsus, an oral semaglutide tablet for the treatment of type 2 diabetes. Five years of real-world use have shown the technology works.
When should I see a doctor?
Common side effects include nausea, vomiting and diarrhoea. They are most likely to appear during dose escalation.
Most gastrointestinal side effects of Wegovy pills are mild and will settle as your body adjusts. However, some symptoms need urgent attention.
Call NHS 111 or attend A&E if you experience:
- Severe abdominal pain radiating to your back (possible pancreatitis)
- Upper right abdominal pain with fever or yellowing skin (gallbladder problems)
- Signs of severe allergic reaction: facial swelling, throat tightness, difficulty breathing
Call 999 for:
- Severe breathing difficulty or loss of consciousness
Contact your prescriber about:
- Persistent vomiting that prevents food or fluid intake
- Significant vision changes
- Thoughts of self-harm
Tell your doctor if you have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
FAQs
How does oral Wegovy work? It contains semaglutide, which mimics GLP-1, your body’s natural fullness signal. You feel satisfied sooner and eat less.
How does semaglutide suppress appetite? It slows stomach emptying and acts on brain receptors that regulate hunger. The effect is the same whether you take the pill or the injection.
What is SNAC technology in Wegovy? SNAC is a compound that protects semaglutide from stomach acid and briefly opens a pathway through the stomach lining so the drug can absorb.
How is oral semaglutide absorption explained? Only about 0.8% of the swallowed dose reaches your bloodstream. Strict fasting rules maximise what gets through.
Why is oral Wegovy dose higher than the injection? Because so little is absorbed. The pill delivers 25mg daily; the weekly injectable delivers 2.4mg. The higher dose compensates for the low absorption.
How does oral semaglutide reach your bloodstream? Through the stomach wall, not the intestine. SNAC creates a brief window for semaglutide to pass through before it is destroyed by digestion.
Key takeaways
- The Wegovy pill contains semaglutide and offers an alternative for people who want to avoid needles. It reduces appetite and slows stomach emptying.
- The fasting rules are strict because the margin for error is narrow. Taking the pill on an empty stomach with minimal water, then waiting 30 minutes, is what makes absorption possible.
- SNAC technology has been in clinical use since 2019. FDA approval for weight management came in December 2025. UK availability is expected following MHRA review in late 2026.
Understanding how oral Wegovy works will help you decide whether the demanding daily routine fits your life. This is the question to discuss with a healthcare professional.
References
A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Rev Endocr Metab Disord. 2022;23(5):979-994.
Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist, Sci Transl Med. 2018;10(467):eaar7047
Current understanding of sodium N-(8-[2-hydroxylbenzoyl] amino) caprylate (SNAC) as an absorption enhancer: the oral semaglutide experience, Clin Diabetes. 2024;42(1):74-86
Clinical pharmacokinetics of oral semaglutide. Clin Pharmacokinet. 2021;60(10):1335-1348
Clinical pharmacokinetics of semaglutide: a systematic review. Drug Des Devel Ther. 2024;18:2555-2570
Oral semaglutide 25 mg in adults with overweight or obesity, N Engl J Med. 2025;393:1077-1087
Wegovy pill approved in the US as first oral GLP-1 for weight management, Novo Nordisk, 22 December 2025 [Accessed 30 March 2026]
Effect of various dosing conditions on the pharmacokinetics of oral semaglutide, a human glucagon-like peptide-1 analogue in a tablet formulation, Diabetes Ther. 2021;12(6):1915-1927.
Authorship

Authored by Shereen Amin
Pharmacist Independent Prescriber & Medical Writer
GPhC: 2073003
Shereen is a Pharmacist Independent Prescriber and medical writer with over ten years' experience across NHS primary care, digital health and specialist services. She writes evidence-based health content for Simple Online Pharmacy, turning complex clinical information into guidance patients can actually use.

Medically Reviewed by Richard Wood
Pharmacist / Clinical Specialist
GPhC reg:
2078802
Richard is a pharmacist and content reviewer at Simple Online Pharmacy. He officially joined the team in 2024 after several years of working with the company as a contractor. Prior to that, he spent over 11 years as a community pharmacist, building a strong foundation in patient care.